FDA Budget In Brief
Drug program proposal: FDA requests $1 billion in fiscal 2011 funding for its human drug program, a 13.6 percent increase from the prior-year appropriation, more than half of which would be covered by user fees. The figure presented Feb. 1 in the Obama administration's proposed budget includes $849.7 million for activities within the Center for Drug Evaluation and Research, and $150.5 million for Office of Regulatory Affairs field operations. The agency seeks $446.5 million for new drug review functions across both CDER and ORA. One area of ORA's domestic program - the OTC monograph project and health fraud project inspections - seeks $95 million for fiscal 2011, which would match the 2010 estimate. Of the $1 billion total for drug activities, $516 million is projected to come from user fees - largely those existing under the Prescription Drug User Fee Act. However, $34.4 million in new generic drug user fees and $2.5 million in field re-inspection user fees are proposed for fiscal 2011. The user fee component would represent 51.6 percent of total drug program funding in fiscal 2011, up from 47.2 percent of the 2010 appropriation
More from Archive
- • By
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
- • By
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
More from Pink Sheet
- • By
It is unclear in a revised staff manual guide whether Commissioner's National Priority Voucher program approval “recommendations” from the drug and biologic center directors will be advisory or decisional, experts told the Pink Sheet.
- • By
Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’
- • By
Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.




